ISL
HRTX icon

Ingalls & Snyder LLC’s Heron Therapeutics HRTX Stock Holding History

Ingalls & Snyder LLC’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5K Hold
11,415
– – ﹤0.01% 477
2026
Q1 		$9K Hold
11,415
– – ﹤0.01% 470
2025
Q4 		$15K Hold
11,415
– – ﹤0.01% 467
2025
Q3 		$14K Hold
11,415
– – ﹤0.01% 481
2025
Q2 		$24K Hold
11,415
– – ﹤0.01% 463
2025
Q1 		$25K Sell
11,415
-2,000
-15% -$3.88K ﹤0.01% 451
2024
Q4 		$21K Hold
13,415
– – ﹤0.01% 445
2024
Q3 		$27K Hold
13,415
– – ﹤0.01% 453
2024
Q2 		$47K Hold
13,415
– – ﹤0.01% 426
2024
Q1 		$37K Buy
13,415
+2,000
+18% +$5.03K ﹤0.01% 440
2023
Q4 		$19K Hold
11,415
– – ﹤0.01% 433
2023
Q3 		$12K Hold
11,415
– – ﹤0.01% 434
2023
Q2 		$13K Hold
11,415
– – ﹤0.01% 433
2023
Q1 		$17K Hold
11,415
– – ﹤0.01% 427
2022
Q4 		$29K Sell
11,415
-2,700
-19% -$8.7K ﹤0.01% 434
2022
Q3 		$60K Hold
14,115
– – ﹤0.01% 419
2022
Q2 		$39K Buy
+14,115
New +$56.7K ﹤0.01% 442

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Ingalls & Snyder LLC's HRTX Position: Q2 2026 in Review

Ingalls & Snyder LLC held its Heron Therapeutics (HRTX) position steady in Q2 2026 at 11,415 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #477.

Ingalls & Snyder LLC first reported a position in HRTX in Q2 2022 and has held it in 17 quarters since. The position peaked at $60K in Q3 2022. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Ingalls & Snyder LLC held 11,415 shares of Heron Therapeutics worth $5K as of Q2 2026.
  • Ingalls & Snyder LLC left its Heron Therapeutics share count unchanged in Q2 2026.
  • Heron Therapeutics made up ﹤0.01% of Ingalls & Snyder LLC's portfolio in Q2 2026, its #477 holding.
  • Ingalls & Snyder LLC first reported a position in Heron Therapeutics in Q2 2022 and has held it in 17 quarters since.
  • Ingalls & Snyder LLC's Heron Therapeutics position peaked at $60K in Q3 2022.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Ingalls & Snyder LLC's 13F filing for Q2 2026, filed 14 Aug 2026.